Trial Profile
A Phase 1/2 Clinical Trial to Assess Safety and Efficacy of a New Treatment for Hodgkin Lymphoma's Disease Combining Adcetris and Levact in Old Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms HALO
- 03 Jan 2023 Status changed from active, no longer recruiting to completed.
- 20 Dec 2022 This trial has been Completed in Italy, According to European Clinical Trials Database
- 02 Jun 2022 Planned End Date changed from 1 Apr 2022 to 1 Dec 2022.